Johnson & Johnson : J&J's Janssen Gets CHMP Positive Opinion for Tremfya in Active Psoriatic Arthritis

By Colin Kellaher

Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of Tremfya for the treatment of adults with active psoriatic arthritis.

The drug maker said it expects a final decision from the European Commission, which generally follows the CHMP's advice, later this year.

Tremfya is currently approved in the EU for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

10-16-20 0821ET